Some very early research into a nontraditional target holds promise for a new line of defense against HIV in decades to come. New compounds that are tentatively being called maturation or assembly inhibitors provide a very early target in HIVs activity within the body, researchers say.
Some very early research into a nontraditional target holds promise for a new line of defense against HIV in decades to come. New compounds that are tentatively being called maturation or assembly inhibitors provide a very early target in HIVs activity within the body, researchers say.
Assembly inhibitors offer hope for future treatment
November 1, 2004